Canaccord Genuity Group Boosts DexCom (NASDAQ:DXCM) Price Target to $145.00

DexCom (NASDAQ:DXCM) had its price objective upped by Canaccord Genuity Group from $144.00 to $145.00 in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a buy rating on the medical device company’s stock.

DXCM has been the subject of a number of other research reports. StockNews.com cut shares of DexCom from a buy rating to a hold rating in a research note on Tuesday. UBS Group upped their target price on DexCom from $153.00 to $163.00 and gave the company a buy rating in a research report on Wednesday, April 10th. Royal Bank of Canada initiated coverage on DexCom in a report on Tuesday, March 12th. They set an outperform rating and a $165.00 price target for the company. Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the company a buy rating in a research report on Wednesday, April 3rd. Finally, Raymond James increased their price target on DexCom from $147.00 to $151.00 and gave the stock a strong-buy rating in a research report on Tuesday, January 23rd. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of Moderate Buy and an average price target of $141.67.

DexCom Trading Down 9.9 %

NASDAQ DXCM opened at $124.34 on Friday. The stock has a market capitalization of $49.24 billion, a price-to-earnings ratio of 80.22, a PEG ratio of 2.37 and a beta of 1.20. DexCom has a 52 week low of $74.75 and a 52 week high of $142.00. The stock’s 50 day moving average price is $131.13 and its two-hundred day moving average price is $118.30. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.38%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. As a group, analysts anticipate that DexCom will post 1.76 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the sale, the chief operating officer now owns 273,913 shares of the company’s stock, valued at $36,816,646.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the sale, the chief operating officer now directly owns 273,913 shares of the company’s stock, valued at approximately $36,816,646.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jereme M. Sylvain sold 11,661 shares of DexCom stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,567,355.01. Following the transaction, the chief financial officer now owns 85,534 shares in the company, valued at approximately $11,496,624.94. The disclosure for this sale can be found here. In the last three months, insiders have sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is owned by insiders.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently modified their holdings of DXCM. DSM Capital Partners LLC bought a new stake in DexCom during the fourth quarter valued at $28,000. Valley National Advisers Inc. boosted its position in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co acquired a new stake in DexCom during the first quarter worth approximately $32,000. MV Capital Management Inc. increased its holdings in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares in the last quarter. Finally, Smithfield Trust Co boosted its holdings in shares of DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.